The viral vector vaccine manufacturing market in the European region is expected to grow at a CAGR of 18.23% during the forecast period of 2019-2027. In the present market scenario, Europe holds the largest market share in manufacturing and distribution of viral vector vaccines. A growing number of clinical trial discovery programs in the region is adding to the growth in the viral vector vaccine manufacturing market. Companies in Germany are increasing clinical trials using viral vectors. German-based, Sartorius announced in January 2018 of the new production facility, opening in France for the GMP manufacturing of viral vectors from non-adherent cell cultures to bring viral vector products from the laboratory to the patients. Viral vectors are increasingly being adopted by livestock producers to minimize livestock deaths due to diseases.

 

EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET FORECAST 2019-2027

Europe Viral Vector Vaccines Manufacturing Market by Types 2019-2027 (Adenoviral Vectors, Retroviral Vectors, Lent Viral Vectors, Adeno-associated Viral Vectors, Poxvirus, Cytomegalovirus, Other Viral Vectors) by Application (Multivalent, Multipathogen) by Diseases (Human Diseases, Veterinary Diseases) by Geography.

Request free sample

Report Summary

The viral vector vaccine manufacturing market in the European region is expected to grow at a CAGR of 18.23% during the forecast period of 2019-2027. In the present market scenario, Europe holds the largest market share in manufacturing and distribution of viral vector vaccines.

A growing number of clinical trial discovery programs in the region is adding to the growth in the viral vector vaccine manufacturing market. Companies in Germany are increasing clinical trials using viral vectors. German-based, Sartorius announced in January 2018 of the new production facility, opening in France for the GMP manufacturing of viral vectors from non-adherent cell cultures to bring viral vector products from the laboratory to the patients. Viral vectors are increasingly being adopted by livestock producers to minimize livestock deaths due to diseases. Thus, increasing prevalence of outbreak of these diseases is supplementing the growth of viral vector vaccines market in the continent.

Leading market players in the European market that manufactures viral vector vaccines are Advanced Biotherapeutics Consulting, Benitec Biopharma, Biovian, Ceva Corporate, Id Pharma Co. Ltd., Brammer Bio, Cell and Gene Therapy Catapult, Boehringer Ingelheim Gmbh, Applied Viromics, Ge Healthcare, Cobra Biologics (Subsidiary of Recip Ab), Janssen Pharmaceutical Inc., Batavia Biosciences, Advanced Bioscience Laboratories Inc. and Biogen Idec (Now Biogen Inc.).

 

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Table of Contents

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • POX VIRUS CONSTITUTES THE LARGEST MARKET SHARE IN TERMS OF TYPES
        • HUMAN DISEASES ARE ANTICIPATED TO GROW SIGNIFICANTLY DURING THE FORECAST PERIOD
        • MULTIVALENT APPLICATIONS ARE WIDELY USED IN THE VIRAL VECTOR MANUFACTURING MARKET
    1. MARKET DETERMINANTS
      • MARKET DRIVERS
        • PROMISING RESULTS FROM SEVERAL CLINICAL STUDIES
        • MOUNTING NUMBER OF VIRAL VECTORS GENE-THERAPY-BASED CLINICAL TRIALS
        • GROWING CHRONIC DISEASES
      • MARKET OPPORTUNITIES
        • SWELLING INVESTMENT IN GENE-THERAPY-BASED R&D ACTIVITIES
        • INCREASE IN THE RESEARCH AND DEVELOPMENT
      • MARKET RESTRAINTS
        • POOR REIMBURSEMENT SYSTEM
        • STRINGENT GOVERNMENT POLICIES
      • MARKET CHALLENGES
        • UNFAVORABLE COMPENSATION SITUATION
        • PRICING PRESSURE COUPLED WITH LACK OF PRODUCT DIFFERENTIATION
        • RIGOROUS REGULATORY AGENDA
    1. MARKET SEGMENTATION
      • MARKET BY TYPES 2019-2027
        • ADENOVIRAL VECTORS
        • RETROVIRAL VECTORS
        • LENTIVIRAL VECTORS
        • ADENO-ASSOCIATED VIRAL VECTORS
        • POXVIRUS
        • CYTOMEGALOVIRUS
        • OTHER VIRAL VECTORS
      • MARKET BY APPLICATION 2019-2027
        • MULTIVALENT
        • MULTIPATHOGEN
      • MARKET BY DISEASES 2019-2027
        • HUMAN DISEASES
          • HEPATITIS
          • CANCER
          • MALARIA
          • TUBERCULOSIS
          • INFLUENZA
          • HIV
          • OTHER HUMAN DISEASES
        • VETERINARY DISEASES
          • AVIAN INFLUENZA
          • MAREK’S DISEASE
          • INFECTIOUS BRONCHITIS
          • PPR DISEASE
          • OTHER VETERINARY DISEASES
    1. KEY ANALYTICS
      • EVOLUTION AND TRANSITION
      • REGULATORY FRAMEWORK
        • EUROPEAN UNION
      • KEY PROPERTIES OF VIRAL VECTOR
      • CHARACTERISTICS OF POTENTIAL VIRAL VACCINE VECTORS
      • PATENT ANALYSIS
        • EUROPE PATENT ANALYSIS
      • MANUFACTURING PROCESS OF A VIRAL-VECTOR
      • SMALL-SCALE MANUFACTURING PROCESS OF ADENOVIRUS
      • KEY SUPPLIERS IN VIRAL VECTOR MARKET
      • KEY BUYING CRITERIA
    2. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • GERMANY
        • THE UNITED KINGDOM
        • FRANCE
        • SPAIN
        • ITALY
        • REST OF THE EUROPE
    1. COMPANY PROFILES
      • ADVANCED BIOTHERAPEUTICS CONSULTING
      • ADVANCED BIOSCIENCE LABORATORIES INC.
      • APPLIED VIROMICS
      • BATAVIA BIOSCIENCES
      • BENITEC BIOPHARMA
      • BIOGEN IDEC (NOW BIOGEN INC.)
      • BIOVIAN
      • BRAMMER BIO
      • BOEHRINGER INGELHEIM GMBH
      • CELL AND GENE THERAPY CATAPULT
      • CEVA CORPORATE
      • COBRA BIOLOGICS (SUBSIDIARY OF RECIP AB)
      • GE HEALTHCARE
      • JANSSEN PHARMACEUTICAL INC.
      • ID PHARMA CO. LTD.

    LIST OF TABLES

    TABLE  1      EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSAND)

    TABLE  2      ONGOING CLINICAL TRIALS RELATED TO VIRAL VECTORS

    TABLE  3      VARIOUS VIRAL VECTORS PROPERTIES AND THEIR APPLICATION IN GENE THERAPY

    TABLE  4      EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

    TABLE  5      KEY VIRAL VECTORS CHARACTERISTICS

    TABLE  6      EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET IN ADENOVIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  7      EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET IN RETROVIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  8      ADVANTAGES AND DISADVANTAGES OF RETROVIRAL VECTORS

    TABLE  9      COMPONENTS OF HIV PROVIRUS

    TABLE  10    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET IN LENTIVIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  11    SECOND- VS. THIRD-GENERATION LENTIVIRAL SYSTEMS

    TABLE  12    AAV VECTORS WITH THEIR TROPISMS AND RECEPTORS

    TABLE  13    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET IN ADENO-ASSOCIATED VIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  14    LICENSED FOWL POX VIRAL-VECTORED VETERINARY VACCINES

    TABLE  15    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET IN POX VIRUS 2019-2027 ($ THOUSANDS)

    TABLE  16    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET IN CYTOMEGALOVIRUS 2019-2027 ($ THOUSANDS)

    TABLE  17    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET IN OTHER VIRAL VECTORS 2019-2027 ($ THOUSANDS)

    TABLE  18    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET BY APPLICATION 2019-2027 ($ THOUSANDS)

    TABLE  19    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET IN MULTIVALENT 2019-2027 ($ THOUSANDS)

    TABLE  20    TB STATISTICS FOR 2016

    TABLE  21    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET IN MULTIPATHOGEN 2019-2027 ($ THOUSANDS)

    TABLE  22    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET BY DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  23    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET IN HUMAN DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  24    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET IN HUMAN DISEASES BY TYPES 2019-2027 ($ THOUSANDS)

    TABLE  25    EUROPE HUMAN DISEASES  MARKET IN HEPATITIS 2019-2027 ($ THOUSANDS)

    TABLE  26    ESTIMATED ACTUAL NEW CASES OF HAV

    TABLE  27    EUROPE HUMAN DISEASES  MARKET IN CANCER 2019-2027 ($ THOUSANDS)

    TABLE  28    EUROPE HUMAN DISEASES  MARKET IN MALARIA 2019-2027 ($ THOUSANDS)

    TABLE  29    MALARIA VACCINE DEVELOPMENT INITIATIVES

    TABLE  30    VIRAL VECTOR VACCINE CANDIDATES FOR TUBERCULOSIS

    TABLE  31    EUROPE HUMAN DISEASES  MARKET IN TUBERCULOSIS 2019-2027 ($ THOUSANDS)

    TABLE  32    EUROPE HUMAN DISEASES  MARKET IN INFLUENZA 2019-2027 ($ THOUSANDS)

    TABLE  33    BENEFITS AND CONCERN FOR VIRUS-VECTORED EXPERIMENTAL INFLUENZA VACCINES

    TABLE  34    EUROPE HUMAN DISEASES  MARKET IN HIV 2019-2027 ($ THOUSANDS)

    TABLE  35    EUROPE HUMAN DISEASES  MARKET IN OTHER HUMAN DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  36    ONGOING CLINICAL TRIALS AND DEVELOPMENT IN ZIKA VIRUS VACCINE

    TABLE  37    LICENSED VIRAL-VECTORED VETERINARY VACCINES

    TABLE  38    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET IN VETERINARY DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  39    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET IN VETERINARY DISEASES BY TYPES  2019-2027 ($ THOUSANDS)

    TABLE  40    AVIAN INFLUENZA VACCINES

    TABLE  41    EUROPE VETERINARY DISEASES MARKET IN AVIAN INFLUENZA 2019-2027 ($ THOUSANDS)

    TABLE  42    EUROPE VETERINARY DISEASES MARKET IN MAREK’S DISEASE 2019-2027 ($ THOUSANDS)

    TABLE  43    MAREK’S DISEASE VACCINES

    TABLE  44    EUROPE VETERINARY DISEASES MARKET IN INFECTIOUS BRONCHITIS 2019-2027 ($ THOUSANDS)

    TABLE  45    EUROPE VETERINARY DISEASES MARKET IN PPR DISEASE 2019-2027 ($ THOUSANDS)

    TABLE  46    EUROPE VETERINARY DISEASES MARKET IN OTHER VETERINARY DISEASES 2019-2027 ($ THOUSANDS)

    TABLE  47    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    TABLE  48    GERMANY VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)

    TABLE  49    THE UNITED KINGDOM VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

    TABLE  50    FRANCE VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

    TABLE  51    SPAIN VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES  2019-2027 ($ THOUSANDS)

    TABLE  52    ITALY VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)

    LIST OF FIGURES

    FIGURE  1    EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSAND)

    FIGURE  2    SCHEMATIC OVERVIEW OF MULTIVALENT AND MULTIPATHOGEN VIRAL VECTOR VACCINES

    FIGURE  3    ESTIMATION OF PEOPLE LIVING WITH HIV 2016 (MILLION)

    FIGURE  4    PREVALENCE OF HBV INFECTION IN THE GENERAL POPULATION 2015 (MILLIONS)

    FIGURE  5    VACCINE ADVANCEMENTS TIMELINE

    FIGURE  6    STEPS REQUIREMENT FOR VACCINE APPROVAL

    FIGURE  7    VACCINE REVIEW AND REGULATION STEPS UNDER EMA

    FIGURE  8    MANUFACTURING PROCESS OF ADENOVIRUS

    FIGURE  9    GERMANY VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    FIGURE  10  THE UNITED KINGDOM VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    FIGURE  11  NUMBER OF PEOPLE LIVING WITH HIV IN FRANCE

    FIGURE  12  FRANCE VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    FIGURE  13  LEADING CAUSES OF WOMEN DEATH IN FRANCE (%)

    FIGURE  14  LEADING CAUSES OF MEN DEATH IN FRANCE (%)

    FIGURE  15  SPAIN VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    FIGURE  16  NUMBER OF PEOPLE IN SPAIN INFECTED WITH HIV

    FIGURE  17  ITALY VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    FIGURE  18  REST OF THE EUROPE VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)

    FIGURE  19  NUMBER OF PEOPLE IN REST OF EUROPE INFECTED WITH HIV (THOUSANDS)

    Segmentation

    1. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • GERMANY
        • THE UNITED KINGDOM
        • FRANCE
        • SPAIN
        • ITALY
        • REST OF THE EUROPE
    1. MARKET SEGMENTATION
      • MARKET BY TYPES 2019-2027
        • ADENOVIRAL VECTORS
        • RETROVIRAL VECTORS
        • LENTIVIRAL VECTORS
        • ADENO-ASSOCIATED VIRAL VECTORS
        • POXVIRUS
        • CYTOMEGALOVIRUS
        • OTHER VIRAL VECTORS
      • MARKET BY APPLICATION 2019-2027
        • MULTIVALENT
        • MULTIPATHOGEN
      • MARKET BY DISEASES 2019-2027
        • HUMAN DISEASES
          • HEPATITIS
          • CANCER
          • MALARIA
          • TUBERCULOSIS
          • INFLUENZA
          • HIV
          • OTHER HUMAN DISEASES
        • VETERINARY DISEASES
          • AVIAN INFLUENZA
          • MAREK’S DISEASE
          • INFECTIOUS BRONCHITIS
          • PPR DISEASE
          • OTHER VETERINARY DISEASES

     

     

    Request Free Sample

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type

      Get In Touch

      Inquire Before Buying

      Customization

      Inkwood Research delivers customized reports as per the client's requirement to provide them with an edge in the competitive market

      Request Customization

      RELATED REPORTS